Swiss pharmaceutical company Curatis Holding AG (SIX:CURN) announced on Friday that it has signed a distribution agreement with healthcare company Phoenix Labs (Ireland) covering four products in Switzerland.

The portfolio includes treatments in pain management and urology and will be available from October 2025.

The products generated around CHF5m in Swiss revenues in 2024.

Under the agreement, Curatis will act as marketing authorisation holder and assume responsibility for regulatory, quality and pharmacovigilance services on behalf of Phoenix Labs in Switzerland.

(EUR1=CHF0.94)